阿尔茨海默病的临床研究进展
Clinical Research Progress of Alzheimer’s Disease
DOI: 10.12677/ACM.2020.1010341, PDF,   
作者: 李晓峰, 王广才：解放军总医院京东医疗区光明桥门诊部保健科，北京；司冰心：空军特色医学中心门诊部保健诊疗科，北京；杜文津*：空军特色医学中心干部病房神经内科，北京
关键词: 阿尔茨海默病；病因；临床研究；综述；Alzheimer Disease； Pathogenesis； Research Achievement； Review
摘要: 阿尔茨海默病(Alzheimer’s disease, AD)是一种进行性，不可逆转，无法治愈的神经退行性疾病，是痴呆最常见的一种。患者主要症状是认知功能持续降低，功能性自立丧失，行为改变，需要人员护理。在我国，由于患者和家属对本病认识的局限，70%的患者确诊时已为重度，错过了最佳干预和治疗时机，到目前为止，还没有一种能够预防或减缓疾病进展的药物。老年痴呆也被称为“无声威胁”，正成为最昂贵的疾病之一，本文对AD的临床研究进展作一综述。
Abstract: Alzheimer’s disease is a progressive, irreversible, incurable, neurodegenerative illness and the most common of the dementing disorders. Slow decline caused by this disease, is characterized by cognitive deterioration, loss of functional independence, changes in behaviour, and expanding needs for care. In our country, due to the limitation of patients’ and their families’ understanding of the disease, 70% of the patients have been diagnosed as severe and missed the best opportunity for intervention and treatment. AD is becoming one of the most problematic and expensive illnesses for the civilization, also known as “silent threat”. This paper has summarized these research achievements of AD.
文章引用：李晓峰, 司冰心, 王广才, 杜文津. 阿尔茨海默病的临床研究进展[J]. 临床医学进展, 2020, 10(10): 2254-2259. https://doi.org/10.12677/ACM.2020.1010341

参考文献

[1] Zvěřová, M. (2019) Clinical Aspects of Alzheimer’s Disease. Clinical Biochemistry, 72, 3-6. [Google Scholar] [CrossRef] [PubMed]
[2] Butcher, H.K., Holkup, P.A. and Buckwalter, K.C. (2001) The Experience of Caring for a Family Member with Alzheimer’s Disease. Western Journal of Nursing Research, 23, 33-55. [Google Scholar] [CrossRef] [PubMed]
[3] Alzheimer’s Association (2018) Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement, 14, 367-429. [Google Scholar] [CrossRef] 
[4] Chhatwal, J.P., Schultz, A.P., Johnson, K.A., et al. (2018) Preferential Degradation of Cognitive Networks Differentiates Alzheimer’s Disease from Ageing. Brain, 141, 1486-1500. [Google Scholar] [CrossRef] [PubMed]
[5] O’Bryant, S.E., Mielke, M.M., Rissman, R.A., et al. (2017) Blood-Based Biomarkers in Alzheimer Disease: Current State of the Science and a Novel Collaborative Paradigm for Advancing from Discovery to Clinic. Alzheimer’s Dement, 13, 45-58. [Google Scholar] [CrossRef] [PubMed]
[6] Kumfor, F. and Piguet, O. (2013) Emotion Recognition in the Dementias: Brain Correlates and Patient Implications. Neurodegenerative Disease Management, 3, 277-288. [Google Scholar] [CrossRef] 
[7] Aschenbrenner, A.J., Gordon, B.A., Benzinger, T.L.S., et al. (2018) Influence of Tau PET, Amyloid PET, and Hippocampal Volume on Cognition in Alzheimer Disease. Neurology, 91, e859-e866. [Google Scholar] [CrossRef] 
[8] Hanseeuw, B.J., Betensky, R.A., Jacobs, H.I.L., et al. (2019) Association of Amyloid and Tau with Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurology, 76, 915-924. [Google Scholar] [CrossRef] [PubMed]
[9] Bussy, A., Snider, B.J., Coble, D., et al. (2019) Dominantly Inherited Alzheimer Network (2019). Effect of Apolipoprotein E4 on Clinical, Neuroimaging, and Biomarker Measures in Noncarrier Participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 75, 42-50. [Google Scholar] [CrossRef] [PubMed]
[10] Bien-Ly, N., Gillespie, A.K., Walker, D., et al. (2012) Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Ab Accumulationin Mutant Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 32, 4803-4811. [Google Scholar] [CrossRef] 
[11] Jiang, Q., Lee, C.Y.D., Mandrekar, S., et al. (2008) ApoE Promotes the Proteolytic Degradation of Abeta. Neuron, 58, 681-693. [Google Scholar] [CrossRef] [PubMed]
[12] Simonsen, A.H., Herukka, S.K., Andreasen, N., et al. (2017) Recommendations for CSF AD Biomarkers in the Diagnostic Evaluation of Dementia. Alzheimer’s Dement, 13, 274-284. [Google Scholar] [CrossRef] [PubMed]
[13] Carbone, I., Lazzarotto, T., Ianni, M., et al. (2014) Herpes Virus in Alzheimer’s Disease: Relation to Progression of the Disease. Neurobiology of Aging, 35, 122-129. [Google Scholar] [CrossRef] [PubMed]
[14] 魏佳慧, 赵峰, 董靖玮, 等. 肠道菌群与阿尔茨海默病的相关性研究进展[J]. 临床医学进展, 2019, 9(5): 703-710.
[15] Perry, R.J., Watson, P. and Hodges, J.R. (2000) The Nature and Staging of Attention Dysfunction in Early (Minimal and Mild) Alzheimer’s Disease: Relationship to Episodic and Semantic Memory Impairment. Neuropsychologia, 38, 252-271. [Google Scholar] [CrossRef] 
[16] Wilkinson, D. and Andersen, H. (2007) Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders, 24, 138-145. [Google Scholar] [CrossRef] [PubMed]
[17] Wattmo, C., Wallin, A.K., Londos, E., et al. (2011) Predictors of Long-Term Cognitive Outcome in Alzheimer’s Disease. Alzheimer’s Research & Therapy, 3, 23. [Google Scholar] [CrossRef] [PubMed]
[18] Han, J.Y., Besser, L.M., Xiong, C., et al. (2019) Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. Alzheimer Disease & Associated Disorders, 33, 87-94. [Google Scholar] [CrossRef] 
[19] Chen, H.S., et al. (1992) Open-Channel Block of N-methyl-D-aspartate (NMDA) Responses by Memantine: Therapeutic Advantage against NMDA Receptor-Mediated Neurotoxicity. Journal of Neuroscience, 12, 4427-4436. [Google Scholar] [CrossRef] 
[20] Matsunaga, S., Kishi, T. and Iwata, N. (2015) Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta Analysis. PLoS ONE, 10, e0123289. [Google Scholar] [CrossRef] [PubMed]
[21] Paul, V.F., David, S., Elliott, D.B., et al. (2019) New Approaches for the Treatment of Alzheimer’s Disease. Bioorganic Medicinal Chemistry Letters, 29, 125-133. [Google Scholar] [CrossRef] [PubMed]
[22] Martin, T., Susan, A. and Marwan, S. (2019) The Path Forward in Alzheimer’s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis. Alzheimer’s Dementia, 1-8.
[23] 周杰. 阿尔茨海默病新药: 中国原研另辟蹊径[J]. 新民周刊, 2019(43): 54-58.
[24] Katsimpardi, L., Litterman, N.K., Schein, P.A., et al. (2014) Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors. Science, 344, 630-634. [Google Scholar] [CrossRef] [PubMed]

为你推荐